Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 1 Interventional

Determining the Safety of CAR T-Cell Therapy for Lymphoma

ClinicalTrials.gov ID: NCT07949058

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07949058. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 4:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Dose-Escalation/Expansion Study of Anti-CD19/CD22 CAR T-Cell Therapy for Relapsed/Refractory Mature B-cell Lymphoma After Prior CD19 CAR T-Cell Failure

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

Study identification

NCT ID
NCT07949058
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
University of Chicago
Other
Enrollment
36 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 13, 2027 (Estimated)
Primary completion
Oct 29, 2031 (Estimated)
Completion
Oct 29, 2031 (Estimated)
Last update posted
Nov 19, 2026

2027 – 2031

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
The University of Chicago Medicine Comprehensive Cancer Center Chicago Illinois 60637 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07949058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2026 · Synced Nov 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.